5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
-
Published:2024-09
Issue:6
Volume:25
Page:502-508.e3
-
ISSN:1525-7304
-
Container-title:Clinical Lung Cancer
-
language:en
-
Short-container-title:Clinical Lung Cancer
Author:
Velcheti Vamsidhar,
Rai PragyaORCID,
Kao Yu-Han,
Chirovsky Diana,
Nunes Ana Tablante,
Liu Stephen V.